Global Diabetic Retinopathy Market Assessment, By Disease Form [Proliferative Diabetic Retinopathy, Non-Proliferative Diabetic Retinopathy], By Treatment [Laser Surgery, Intraocular Steroid Injection, Vitrectomy, Anti-VEGF, Others], By End-user [Hospitals, Ophthalmic Centers, Ambulatory Surgical Centers, Others], By Region, Opportunities and Forecast, 2017-2031F

The global diabetic retinopathy market is undergoing significant expansion because of the increase in the demand for anti-VEGF medications to treat diabetic retinopathy.

Home>Industry Reports>Global Diabetic Retinopathy Market Assessment, Opportunities and Forecast, 2017-2031F

The global diabetic retinopathy market is projected to witness a CAGR of 6.26% during the forecast period 2024-2031, growing from USD 9.03 billion in 2023 to USD 14.68 billion in 2031. The global diabetic retinopathy market is being driven by various factors, such as the increasing prevalence of diabetes, technological advancements, an increasing number of diabetes related disorders, growing demand for non-proliferative diabetic retinopathy, and increasing popularity of anti-VEGF medications. Advancements in cutting-edge technologies, especially the integration of artificial intelligence, play an important role in influencing the global diabetic retinopathy market. AI is responsible for improving the speed and accuracy of diagnosis by analyzing large amounts of complex data for patterns that indicate diabetic retinopathy. Both public and private firms are investing significantly in diabetic retinopathy related technologies. These investments are used for R&D purposes, which help in developing advanced solutions for the market. Often, public and private firms utilize each other’s strengths to spur innovation in the global diabetic retinopathy market, which, in turn, helps expand the market demand.

Another important aspect influencing the global diabetic retinopathy market is the increasing prevalence of diabetes. Diabetic retinopathy is found in patients, where diabetes is not detected in the early stages or the patients who don’t receive proper treatment. Early care is key to preventing the disease's progression, so there is a greater demand for medications for non-proliferative DR which is an early stage of the disease. Patients prefer non-invasive forms of treatment for treating diabetic retinopathy, such as medications. These medications have proven to be highly effective in combatting the disease. Major market players are conducting clinical trials, which leads to the discovery of effective and innovative drugs.

In November 2023, Exonate Ltd, a mRNA therapy company involved in creating solutions for the treatment of diabetic complications, announced the successful completion of a clinical trial for EXN407, its lead asset for ophthalmology. EXN407 is the first topical treatment for diabetic macular edema and diabetic retinopathy.

Download Free Sample Report

Technological Advancements

The expansion of the global diabetic retinopathy market is being significantly affected by advancing technologies, specifically related to AI. The integration of AI improves the detection efficiency and accuracy of diabetic retinopathy by using advanced diagnosis tools. Through AI algorithms, physicians can predict the chances of a patient developing diabetic retinopathy earlier with high accuracy. This capability is crucial for early prognosis since it makes timely interventions that might save lives. As a result, AI is causing a revolution in the field of diabetic retinopathy, improving outcomes and accelerating the expansion of the enterprise. Also, the use of injectable medications and laser technologies helps diabetic retinopathy effectively. In April 2023, Sankara Nethralaya, an eye hospital based in Chennai, India, announced its partnership with RetinaRisk, a health tech company from Iceland, to adopt a mathematical tool to predict the chances of a person developing diabetic retinopathy.

Significant Investments by Key Market Players

Another significant market trend includes significant investments by various medical device companies to drive innovation and technological advancements in the global diabetic retinopathy market. This access to funding is necessary to enable the development of new strategies for the detection of diabetic retinopathy and technologies to enhance research and development initiatives. To create new treatments for diabetic retinopathy, pharmaceutical companies are heavily funding research and development. Additionally, partnerships between pharmaceutical companies, academic institutions, and healthcare organizations are assisting in the development of cutting-edge diabetic retinopathy therapies. Combination therapies, which use several medications or therapeutic modalities, are becoming more and more popular in the management of diabetic retinopathy.

On 14th february 2024, the Advanced Research Projects Agency for Health (ARPA-H) granted funding of $20 million to a biomedical engineering professor in the McKelvey School of Engineering at Washington University. The contract is a component of ARPA-H's initial request for proposals, which aims to provide innovative methods for enhancing health outcomes for various patient populations, communities, diseases, and health conditions using ground-breaking research and cutting-edge technologies.

Increasing Demand for Non-Proliferative Diabetic Retinopathy Medications

The growing need for therapies that address the early stages of the illness, known as non-proliferative diabetic retinopathy (NPDR), is a major factor driving the growth of the global diabetic retinopathy market. The need for early detection and treatment of diabetic eye problems has increased due to the global rise in the prevalence of diabetes. The goal of NPDR treatments is to prevent or slow the disease's advancement to its more serious proliferative stages, which increases the risk of complete loss of vision. Increased awareness and use of advanced screening procedures have led to an earlier detection of the condition, thus surging the demand for these drugs. The global diabetic retinopathy market is being driven by this trend, which incentivizes pharmaceutical companies to heavily invest in the study to develop specialized treatments for NPDR.

OcuTerra Therapeutics, Inc., a clinical-stage ophthalmology company, announced in July 2023 that the clinical trial assessing OTT168 topical eye drops for adult patients with moderately severe to severe non-proliferative diabetic retinopathy has completed enrollment in the Phase 2 DR:EAM trial (Diabetic Retinopathy: Early Active Management).

Growing Popularity of Anti-VEGF Medications

The global diabetic retinopathy market is undergoing significant expansion due to the increasing demand for anti-VEGF medications to treat diabetic retinopathy. Anti-VEGF medications are used to treat early symptoms of diabetic retinopathy to prevent further vascular leakage, reduce inflammation, and prevent loss of vision. Anti-VEGF medications, such as aflibercept and ranibizumab, stop the abnormal blood vessels behind the retina from rupturing, expanding, and eventually bleeding. Vascular endothelial growth factor (VEGF) is a protein that causes aberrant blood vessels to form in the retina, and anti-VEGF works against this protein.

In April 2023, Ximluci, a ranibizumab biosimilar, was introduced in many European countries by STADA Arzneimittel, a pharmaceutical company, Xbrane Biopharma, based in Sweden.

North America Dominates the Market

North American countries possess a robust healthcare ecosystem that is concentrated with technologically advanced medical device and pharmaceutical companies. The region leads the global diabetic retinopathy market for a variety of reasons. The area has a higher-than-average incidence of diabetic retinopathy driven by the growing aging population and sedentary lifestyles. The public is also aware of diabetes and its complications, which promotes early detection and intervention. Furthermore, North America is known for its emphasis on research and development, along with advanced healthcare infrastructure and significant healthcare budgets, which makes it easier to obtain state-of-the-art diabetes treatments and diagnostics. 

In April 2023, the LumineticsCore AI diagnostic system was launched by Digital Diagnostics, an AI-based diagnostic healthcare company, in the southeast region of the US. It is an FDA-approved device that helps in examining the retinal images of people suffering from diabetic retinopathy.

Future Market Scenario (2024 – 2031F)

·         The future of the global diabetic retinopathy market includes smart devices that will enable the diagnosis of diabetic retinopathy without the need for human intervention.

·         Globally, many children are being diagnosed with type-1 and type-2 diabetes, thus increasing the number of childhood hyperglycaemia cases, which are associated with an increased risk of developing diabetic retinopathy in the future.

·         The introduction of a new class of therapeutics called “Stress Resilience-Enhancing Drugs” (SREDs) is going to drive the global diabetic retinopathy market. Through phosphodiesterase inhibition, these medications protect the structure and function of the degenerating retina.

·         Biomarkers and OCTA (Optical Coherence Tomography Angiography) are being used extensively for assessing and monitoring diabetic retinopathy and diabetic macular edema. Biomarkers provide an in vivo assessment of the health of the retina and choroid non-invasively. OCTA, on the other hand, offers detailed information on the retinochoroidal microvasculature, including precise areas of capillary non-perfusion, presence of collaterals or retinal/optic nerve head neovascularization, and abnormalities of the foveal avascular zone.

Report Scope

“Diabetic Retinopathy Market Assessment, Opportunities, and Forecast, 2017-2031F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of the global diabetic retinopathy market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2024 and 2031F. Additionally, the report profiles the leading players in the industry mentioning their respective market share, business model, competitive intelligence, etc.

Report Attribute

Details

Base Year of the Analysis

2023

Historical Period

2017-2022

Forecast Period

2024-2031F

Projected Growth Rate

CAGR of 6.26% between 2024 and 2031F

Revenue Forecast in 2031

USD 14.68 billion

Segments Covered

Disease Form, Treatment, End-user

Regions Covered

North America, Europe, South America, Asia-Pacific, Middle East and Africa

Key Companies Profile

Alimera Sciences, Inc., AbbVie, Inc., Regeneron Pharmaceuticals, Inc., Ampio Pharmaceuticals, Inc., Bayer AG, F. Hoffmann-La Roche Ltd., Sirnaomics Ltd, Kowa Co Ltd, Ocuphire Pharma, Inc., Oxurion NV

Customization Scope

15% free report customization with purchase

Pricing and Purchase Options

Avail the customized purchase options to fulfill your precise research needs

Delivery Format

PDF and Excel through email (subject to the license purchased)

In this report, the global diabetic retinopathy market has been segmented into the following categories: 

·         By Disease Form

o   Proliferative Diabetic Retinopathy

o   Non-Proliferative Diabetic Retinopathy

·         By Treatment

o   Laser Surgery

o   Intraocular Steroid Injection

o   Vitrectomy

o   Anti-VEGF

o   Others

·         By End-user

o   Hospitals

o   Ophthalmic Centers

o   Ambulatory Surgical Centers

o   Others

·         By Region

o   North America

o   Europe

o   Asia-Pacific

o   South America

o   Middle East and Africa

Key Players Landscape and Outlook

To strengthen their position in the market and expedite the creation and dissemination of cutting-edge therapies, major players in the global diabetic retinopathy market are forming partnerships. Through partnerships, companies can broaden their geographic reach and penetrate new markets by capitalizing on the regulatory and local expertise of their partners. This cooperative strategy promotes competition, which can result in better patient outcomes and cost savings, in addition to advancing the development of more accessible and effective treatments for diabetic retinopathy.

In November 2023, Lupin Ltd, an Indian multinational pharmaceutical company, and Amman Pharma, one of the first pharmaceutical companies in the MENA region, entered a collaboration for the supply and licensing of Ranibizumab in the Middle East and North Africa region, including Iraq, Saudi Arabia, Jordan, the UAE, Lebanon and other GCC countries. It is a biosimilar drug used for the treatment of diabetic retinopathy.

Key Players Operating in the Global Diabetic Retinopathy Market are:

·         Alimera Sciences, Inc.

·         AbbVie, Inc.

·         Regeneron Pharmaceuticals, Inc.

·         Ampio Pharmaceuticals, Inc.

·         Bayer AG

·         F. Hoffmann-La Roche Ltd.

·         Sirnaomics Ltd

·         Kowa Co Ltd

·         Ocuphire Pharma, Inc.

·         Oxurion NV

Markets and Data’s reports answer the following questions:

·         What is the current and future market size of the product/service in question globally or specific to different countries?

·         How are the markets divided into different product/service segments and the market size and growth of each segment?

·         What is the market potential of different product segments and their investment case?

·         How are the markets predicted to develop in the future and what factors will drive or inhibit growth?

·         What is the business environment and regulatory landscape specific to the product/service?

If you can't find what you're searching for or have any custom requirements for the global diabetic retinopathy market, you may approach our team at info@marketsandata.com.

Table of Contents

1.       Research Methodology

2.       Project Scope & Definitions

3.       Executive Summary

4.       Global Diabetic Retinopathy Market Outlook, 2017-2031F

4.1.    Market Size & Forecast

4.1.1.By Value

4.1.2.By Volume

4.2.    By Disease Form

4.2.1.Proliferative Diabetic Retinopathy

4.2.2.Non-Proliferative Diabetic Retinopathy

4.3.    By Treatment

4.3.1.Laser Surgery

4.3.2.Intraocular Steroid Injection

4.3.3.Vitrectomy

4.3.4.Anti-VEGF

4.3.5.Others

4.4.    By End-user

4.4.1.Hospitals

4.4.2.Ophthalmic Centers

4.4.3.Ambulatory Surgical Centers

4.4.4.Others

4.5.    By Region

4.5.1.  North America

4.5.2.  Europe

4.5.3.  Asia-Pacific

4.5.4.  South America

4.5.5.  Middle East and Africa

4.6.    By Company Market Share (%), 2023

5.       Global Diabetic Retinopathy Market Outlook, By Region, 2017-2031F

5.1.    North America*

5.1.1.Market Size & Forecast

5.1.1.1.               By Value

5.1.1.2.               By Volume

5.1.2.By Disease Form

5.1.2.1.              Proliferative Diabetic Retinopathy

5.1.2.2.              Non-Proliferative Diabetic Retinopathy

5.1.3.By Treatment

5.1.3.1.              Laser Surgery

5.1.3.2.              Intraocular Steroid Injection

5.1.3.3.              Vitrectomy

5.1.3.4.              Anti-VEGF

5.1.3.5.              Others

5.1.4.By End-user

5.1.4.1.              Hospitals

5.1.4.2.              Ophthalmic Centers

5.1.4.3.              Ambulatory Surgical Centers

5.1.4.4.              Others

5.1.5.United States*

5.1.5.1.              Market Size & Forecast

5.1.5.1.1.                    By Value

5.1.5.1.2.                    By Volume

5.1.5.2.              By Disease Form

5.1.5.2.1.                    Proliferative Diabetic Retinopathy

5.1.5.2.2.                    Non-Proliferative Diabetic Retinopathy

5.1.5.3.              By Treatment

5.1.5.3.1.                    Laser Surgery

5.1.5.3.2.                    Intraocular Steroid Injection

5.1.5.3.3.                    Vitrectomy

5.1.5.3.4.                    Anti-VEGF

5.1.5.3.5.                    Others

5.1.5.4.              By End-user

5.1.5.4.1.                    Hospitals

5.1.5.4.2.                    Ophthalmic Centers

5.1.5.4.3.                    Ambulatory Surgical Centers

5.1.5.4.4.                    Others

5.1.6.Canada

5.1.7.Mexico

*All segments will be provided for all regions and countries covered

5.2.    Europe

5.2.1.Germany

5.2.2.France

5.2.3.Italy

5.2.4.United Kingdom

5.2.5.Russia

5.2.6.Netherlands

5.2.7.Spain

5.2.8.Turkey

5.2.9.Poland

5.3.    Asia-Pacific

5.3.1.India

5.3.2.China

5.3.3.Japan

5.3.4.Australia

5.3.5.Vietnam

5.3.6.South Korea

5.3.7.Indonesia

5.3.8.Philippines

5.4.    South America

5.4.1.Brazil

5.4.2.Argentina

5.5.    Middle East & Africa

5.5.1.Saudi Arabia

5.5.2.UAE

5.5.3.South Africa

6.       Market Mapping, 2023

6.1.    By Disease Form

6.2.    By Treatment

6.3.    By End-user

6.4.    By Region

7.       Macro Environment and Industry Structure

7.1.   Demand Supply Analysis

7.2.   Import Export Analysis

7.3.   Value Chain Analysis

7.4.   PESTEL Analysis

7.4.1.Political Factors

7.4.2.Economic System

7.4.3.Social Implications

7.4.4.Technological Advancements

7.4.5.Environmental Impacts

7.4.6.Legal Compliances and Regulatory Policies (Statutory Bodies Included)

7.5.   Porter’s Five Forces Analysis

7.5.1.Supplier Power

7.5.2.Buyer Power

7.5.3.Substitution Threat

7.5.4.Threat from New Entrant

7.5.5.Competitive Rivalry

8.       Market Dynamics

8.1.    Growth Drivers

8.2.    Growth Inhibitors (Challenges and Restraints)

9.       Regulatory Framework and Innovation

9.1.    Clinical Trials

9.2.    Patent Landscape

9.3.    Regulatory Approvals

9.4.    Innovations/Emerging Technologies

10.   Key Players Landscape

10.1.  Competition Matrix of Top Five Market Leaders

10.2.  Market Revenue Analysis of Top Five Market Leaders (in %, 2023)

10.3.  Mergers and Acquisitions/Joint Ventures (If Applicable)

10.4.  SWOT Analysis (For Five Market Players)

10.5.  Patent Analysis (If Applicable)

11.   Pricing Analysis

12.   Case Studies

13.   Key Players Outlook

13.1.         Alimera Sciences, Inc

13.1.1.   Company Details

13.1.2.   Key Management Personnel

13.1.3.   Products & Services

13.1.4.   Financials (As reported)

13.1.5.   Key Market Focus & Geographical Presence

13.1.6.   Recent Developments

13.2.         AbbVie Inc

13.3.         Regeneron Pharmaceuticals Inc

13.4.         Ampio Pharmaceuticals, Inc.

13.5.         Bayer AG

13.6.         F. Hoffmann-La Roche Ltd.

13.7.         Sirnaomics Ltd

13.8.         Kowa Co Ltd

13.9.         Ocuphire Pharma, Inc.

13.10.      Oxurion NV 

*Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work. 

14.   Strategic Recommendations

15.   About Us & Disclaimer

List of Figures:

Figure 1. Global Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 2. Global Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 3. Global Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 4. Global Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 5. Global Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 6. Global Diabetic Retinopathy Market Share (%), By Region, 2017-2031F

Figure 7. North America Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 8. North America Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 9. North America Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 10. North America Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 11. North America Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 12. North America Diabetic Retinopathy Market Share (%), By Country, 2017-2031F

Figure 13. United States Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 14. United States Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 15. United States Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 16. United States Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 17. United States Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 18. Canada Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 19. Canada Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 20. Canada Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 21. Canada Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 22. Canada Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 23. Mexico Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 24. Mexico Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 25. Mexico Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 26. Mexico Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 27. Mexico Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 28. Europe Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 29. Europe Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 30. Europe Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 31. Europe Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 32. Europe Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 33. Europe Diabetic Retinopathy Market Share (%), By Country, 2017-2031F

Figure 34. Germany Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 35. Germany Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 36. Germany Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 37. Germany Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 38. Germany Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 39. France Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 40. France Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 41. France Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 42. France Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 43. France Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 44. Italy Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 45. Italy Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 46. Italy Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 47. Italy Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 48. Italy Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 49. United Kingdom Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 50. United Kingdom Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 51. United Kingdom Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 52. United Kingdom Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 53. United Kingdom Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 54. Russia Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 55. Russia Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 56. Russia Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 57. Russia Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 58. Russia Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 59. Netherlands Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 60. Netherlands Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 61. Netherlands Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 62. Netherlands Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 63. Netherlands Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 64. Spain Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 65. Spain Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 66. Spain Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 67. Spain Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 68. Spain Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 69. Turkey Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 70. Turkey Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 71. Turkey Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 72. Turkey Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 73. Turkey Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 74. Poland Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 75. Poland Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 76. Poland Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 77. Poland Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 78. Poland Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 79. South America Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 80. South America Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 81. South America Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 82. South America Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 83. South America Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 84. South America Diabetic Retinopathy Market Share (%), By Country, 2017-2031F

Figure 85. Brazil Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 86. Brazil Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 87. Brazil Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 88. Brazil Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 89. Brazil Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 90. Argentina Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 91. Argentina Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 92. Argentina Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 93. Argentina Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 94. Argentina Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 95. Asia-Pacific Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 96. Asia-Pacific Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 97. Asia-Pacific Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 98. Asia-Pacific Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 99. Asia-Pacific Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 100. Asia-Pacific Diabetic Retinopathy Market Share (%), By Country, 2017-2031F

Figure 101. India Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 102. India Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 103. India Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 104. India Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 105. India Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 106. China Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 107. China Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 108. China Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 109. China Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 110. China Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 111. Japan Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 112. Japan Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 113. Japan Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 114. Japan Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 115. Japan Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 116. Australia Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 117. Australia Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 118. Australia Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 119. Australia Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 120. Australia Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 121. Vietnam Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 122. Vietnam Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 123. Vietnam Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 124. Vietnam Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 125. Vietnam Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 126. South Korea Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 127. South Korea Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 128. South Korea Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 129. South Korea Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 130. South Korea Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 131. Indonesia Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 132. Indonesia Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 133. Indonesia Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 134. Indonesia Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 135. Indonesia Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 136. Philippines Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 137. Philippines Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 138. Philippines Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 139. Philippines Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 140. Philippines Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 141. Middle East & Africa Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 142. Middle East & Africa Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 143. Middle East & Africa Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 144. Middle East & Africa Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 145. Middle East & Africa Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 146. Middle East & Africa Diabetic Retinopathy Market Share (%), By Country, 2017-2031F

Figure 147. Saudi Arabia Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 148. Saudi Arabia Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 149. Saudi Arabia Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 150. Saudi Arabia Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 151. Saudi Arabia Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 152. UAE Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 153. UAE Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 154. UAE Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 155. UAE Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 156. UAE Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 157. South Africa Diabetic Retinopathy Market, By Value, in USD Billion, 2017-2031F

Figure 158. South Africa Diabetic Retinopathy Market, By Volume, in Million Units, 2017-2031F

Figure 159. South Africa Diabetic Retinopathy Market Share (%), By Disease Form, 2017-2031F

Figure 160. South Africa Diabetic Retinopathy Market Share (%), By Treatment, 2017-2031F

Figure 161. South Africa Diabetic Retinopathy Market Share (%), By End-user, 2017-2031F

Figure 162. By Disease Form Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 163. By Treatment Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 164. By End-user Map-Market Size (USD Billion) & Growth Rate (%), 2023

Figure 165. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2023

List of Tables

Table 1. Pricing Analysis of Products from Key Players

Table 2. Competition Matrix of Top 5 Market Leaders

Table 3. Mergers & Acquisitions/ Joint Ventures (If Applicable)

Table 4. About Us - Regions and Countries Where We Have Executed Client Projects

What are the regions covered in the final report for the global diabetic retinopathy market?

arrowup
Heart

Global E-bike Battery Market Assessment, Opportunities and Forecast, 2017-2031F

The increased popularity of e-bikes along with the increasing adoption of compact vehicles for adventure sport and exploration is propelling the market expansion. ....Read More

Published on

April 2024

4,500

Heart

Global Chloroxylenol Market Assessment, Opportunities and Forecast, 2017-2031F

Global chloroxylenol market is expected to experience significant growth over the forecast period owing to the antimicrobial properties of chloroxylenol, increasing emphasis on maintaining skin health and personal hygiene, and growing threat of surgi....Read More

Published on

April 2024

4,500

Heart

Global Gabapentin Market Assessment, Opportunities and Forecast, 2017-2031F

Global gabapentin market will experience significant growth over the forecast period due to the rising investments in product innovation activities by the pharmaceutical companies and increasing incidences of seizures.....Read More

Published on

April 2024

4,500

Heart

Global Magnesium Citrate Market Assessment, Opportunities and Forecast, 2017-2031F

Global magnesium citrate market will witness significant growth over the forecast period owing to rapid expansion of the pharmaceutical sector and increasing research and development activities.....Read More

Published on

April 2024

4,500

Purchase Options

USD ($)

arrowdown

i

3,000

i

4,500

i

5,700

i

8,200

Tired of Searching?

Looking for Customization?

Some other doubt?

Need insights from a cohort?

REACH US

    icon_Five
    17, Okhla Industrial Estate Phase 3 Rd, Okhla Phase III, Okhla Industrial Estate, New Delhi, Delhi 110020
    call_Two
    +91 11 42343567
    icon_Six
    info@marketsandata.com
icon_Seven
5741 Cleveland street, Suite 120, VA beach, VA, USA 23462
call_Three
+1 (757) 343-3258
icon_Eight
190 Middle Road, # 14-10 Fortune Centre, Singapore -188979